Monocyte HLA-DR Measurement by Flow Cytometry in COVID-19 Patients: An Interim Review.
COVID-19
HLA-DR
flow cytometry
sepsis
Journal
Cytometry. Part A : the journal of the International Society for Analytical Cytology
ISSN: 1552-4930
Titre abrégé: Cytometry A
Pays: United States
ID NLM: 101235694
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
16
10
2020
revised:
23
10
2020
accepted:
27
10
2020
pubmed:
31
10
2020
medline:
22
12
2020
entrez:
30
10
2020
Statut:
ppublish
Résumé
Several months after the sudden emergence of SARS-CoV-2 and COVID-19, the understanding of the appropriate host immune response to a virus totally unknown of human immune surveillance is still of major importance. By international definition, COVID-19 falls in the scope of septic syndromes (organ dysfunction due to dysregulated host response to an infection) in which immunosuppression is a significant driver of mortality. Sepsis-induced immunosuppression is mostly defined and monitored by the measurement of decreased expression of HLA-DR molecules on circulating monocytes (mHLA-DR). In this interim review, we summarize the first mHLA-DR results in COVID-19 patients. In critically ill patients, results homogenously indicate a decreased mHLA-DR expression, which, along with profound lymphopenia and other functional alterations, is indicative of a status of immunosuppression. © 2020 International Society for Advancement of Cytometry.
Identifiants
pubmed: 33125816
doi: 10.1002/cyto.a.24249
doi:
Substances chimiques
HLA-DR Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1217-1221Subventions
Organisme : Claude Bernard Lyon I University
Pays : International
Organisme : Hospices Civils de Lyon
Pays : International
Informations de copyright
© 2020 International Society for Advancement of Cytometry.
Références
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395:1054-1062.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061-1069.
Huang W, Berube J, McNamara M, Saksena S, Hartman M, Arshad T, Bornheimer SJ, O'Gorman M. Lymphocyte subset counts in COVID-19 patients: A meta-analysis. Cytom Part A 2020;97A:772-776.
Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y, Swartz TH, Madduri D, Stock A, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020;26:1636-1643.
Aziz M, Fatima R, Assaly R. Elevated interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol 2020;92:2283-2285.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016;315:801-810.
Monneret G, Gossez M, Aghaeepour N, Gaudilliere B, Venet F. How clinical flow cytometry rebooted sepsis immunology. Cytom Part A 2019;95A:431-441.
Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: From cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13:862-874.
Venet F, Monneret G. Advances in the understanding and treatment of sepsis-induced immunosuppression. Nat Rev Nephrol 2018;14:121-137.
Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: A double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009;180:640-648.
Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, Monneret G, Rimmele T, Blood T, Morre M, et al. Interleukin-7 restores lymphocytes in septic shock: The IRIS-7 randomized clinical trial. JCI Insight 2018;3:e98960.
Venet F, Demaret J, Gossez M, Monneret G. Myeloid cells in sepsis-acquired immunodeficiency. Ann N Y Acad Sci 2020. https://doi.org/10.1111/nyas.14333.
Biswas SK, Lopez-Collazo E. Endotoxin tolerance: New mechanisms, molecules and clinical significance. Trends Immunol 2009;30:475-487.
Wolk K, Docke WD, von Baehr V, Volk HD, Sabat R. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 2000;96:218-223.
Pickkers P, Kox M. Towards precision medicine for sepsis patients. Crit Care 2017;21:11.
Galbraith N, Walker S, Carter J, Polk HC Jr. Past, present, and future of augmentation of monocyte function in the surgical patient. Surg Infect (Larchmt) 2016;17:563-569.
Mengos AE, Gastineau DA, Gustafson MP. The CD14(+)HLA-DR(lo/neg) monocyte: An immunosuppressive phenotype that restrains responses to cancer immunotherapy. Front Immunol 2019;10:1147.
Remy S, Gossez M, Belot A, Hayman J, Portefaix A, Venet F, Javouhey E, Monneret G. Massive increase in monocyte HLA-DR expression can be used to discriminate between septic shock and hemophagocytic lymphohistiocytosis-induced shock. Crit Care 2018;22:213.
Laing AG, Lorenc A, del Molino Del Barrio I, Das A, Fish M, Monin L, Munoz-Ruiz M, DR MK, Hayday TS, Francos-Quijorna I, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med 2020;26(10):1623-1635.
Arunachalam PS, Wimmers F, Mok CKP, Perera R, Scott M, Hagan T, Sigal N, Feng Y, Bristow L, Tak-Yin Tsang O, et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science 2020;369:1210-1220.
Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa L, Almire C, Henon C, Kosmider O, Droin N, et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell 2020;182:1401-1418 e18.
Schulte-Schrepping J, Reusch N, Paclik D, Bassler K, Schlickeiser S, Zhang B, Kramer B, Krammer T, Brumhard S, Bonaguro L, et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell 2020;182:1419-1440 e23.
Moratto D, Chiarini M, Giustini V, Serana F, Magro P, Roccaro AM, Imberti L, Castelli F, Notarangelo LD, Quiros-Roldan E. Flow cytometry identifies risk factors and dynamic changes in patients with COVID-19. J Clin Immunol 2020;40:970-973.
Gatti A, Radrizzani D, Vigano P, Mazzone A, Brando B. Decrease of non-classical and intermediate monocyte subsets in severe acute SARS-CoV-2 infection. Cytom Part A 2020;97A:887-890.
Peruzzi B, Bencini S, Capone M, Mazzoni A, Maggi L, Salvati L, Vanni A, Orazzini C, Nozzoli C, Morettini A, et al. Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection. Immunology 2020. https://doi.org/10.1111/imm.13254.
Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, Damoraki G, Gkavogianni T, Adami ME, Katsaounou P, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 2020;27:992-1000.
Monneret G, Cour M, Viel S, Venet F, Argaud L. Coronavirus disease 2019 as a particular sepsis: A 2-week follow-up of standard immunological parameters in critically ill patients. Intensive Care Med 2020;46(9):1764-1765.
Kox M, Frenzel T, Schouten J, van de Veerdonk FL, Koenen H, Pickkers P, Group obotRCIC-s. COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients. Crit Care 2020;24:263.
Jeannet R, Daix T, Formento R, Feuillard J, Francois B. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression. Intensive Care Med 2020;46:1769-1771.
Spinetti T, Hirzel C, Fux M, Walti LN, Schober P, Stueber F, Luedi MM, Schefold JC. Reduced monocytic HLA-DR expression indicates immunosuppression in critically ill COVID-19 patients. Anesth Analg 2020;131:993-999.
Monneret G, de Marignan D, Coudereau R, Bernet C, Ader F, Frobert E, Gossez M, Viel S, Venet F, Wallet F. Immune monitoring of interleukin-7 compassionate use in a critically ill COVID-19 patient. Cell Mol Immunol 2020;17:1001-1003.
Wang F, Hou H, Yao Y, Wu S, Huang M, Ran X, Zhou H, Liu Z, Sun Z. Systemically comparing host immunity between survived and deceased COVID-19 patients. Cell Mol Immunol 2020;17:875-877.
Hue S, Beldi-Ferchiou A, Bendib I, Surenaud M, Fourati S, Frapard T, Rivoal S, Razazi K, Carteaux G, Delfau-Larue MH, et al. Uncontrolled innate and impaired adaptive immune responses in patients with COVID-19 ARDS. Am J Respir Crit Care Med 2020. https://doi.org/10.1164/rccm.202005-1885OC.
Zhou R, To KK, Wong YC, Liu L, Zhou B, Li X, Huang H, Mo Y, Luk TY, Lau TT, et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity 2020;53:864-877.
Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol 2020;20:397-398.
Monneret G, Gossez M, Venet F. Sepsis and immunosenescence: Closely associated in a vicious circle. Aging Clin Exp Res 2019. https://doi.org/10.1007/s40520-019-01350-z.
Sinha P, Calfee CS, Cherian S, Brealey D, Cutler S, King C, Killick C, Richards O, Cheema Y, Bailey C, et al. Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: A prospective observational study. Lancet Respir Med 2020. https://doi.org/10.1016/S2213-2600(20)30366-0.
Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, Guo L, Yang J, Wang C, Jiang S, et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe 2020;27:883-890.